Should I Buy FDMT Stock in 2026?

Data-driven analysis and honest assessment for 4D Molecular Therapeutics Inc

Analysis Updated:
CAUTIONSeveral concerns warrant careful consideration

Current Price: $8.46

Decision Score

4.4/10

Weak

Based on 6 fundamental factors

Score Breakdown:

Valuation (20%)5/10

P/E data not available

Growth (20%)7/10

Solid growth of 14%

Profitability (20%)2/10

Currently unprofitable

Financial Health (15%)5/10

Financial health data limited

Cash Flow (15%)2/10

Negative free cash flow

Insider Activity (10%)5/10

No recent insider activity

Key Investment Metrics

Current Price

$8.46

P/E Ratio

N/A

Revenue Growth

29.0%

Profit Margin

N/A

Market Cap

$0.5B

Dividend Yield

None

How FDMT Compares to Competitors

Understanding how FDMT stacks up against peers helps inform your investment decision.

How FDMT Compares to Peers

Upcoming Events for FDMT

+5 Reasons TO Buy FDMT

1. Revenue growing 29% year-over-year

strong

Strong top-line growth indicates robust demand and expanding market opportunity.

-5 Reasons NOT to Buy FDMT

1. Negative free cash flow

high risk

Burning cash creates funding risk and limits shareholder returns.

2. Small-cap volatility risk

medium risk

Market cap under $2B means higher volatility and lower liquidity.

Who Should Buy FDMT?

Investment Profile

Risk Level

Very High

Recommended Holding Period

3-5 years

Best For:

  • Growth Investors

    29% revenue growth aligns with growth strategies

Not Suitable For:

  • Income-Focused Retirees

    No dividend paid

  • Risk-Averse Investors

    Very High risk may cause uncomfortable volatility

  • Large Position Traders

    Lower liquidity may impact execution

Consider These Alternatives

If you're interested in FDMT, compare these Health Care peers:

Pro tip: Compare FDMT directly with competitors using our comparison tool to see which stock better fits your criteria.

Get the Full Picture

Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for FDMT

Frequently Asked Questions

What is FDMT stock price today?

FDMT (4D Molecular Therapeutics Inc) stock is trading at $8.46 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is FDMT stock going up or down today?

FDMT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy FDMT stock now?

The decision to buy FDMT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is FDMT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for FDMT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is FDMT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if FDMT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is FDMT's P/E ratio?

P/E ratio data for FDMT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is FDMT's market cap?

FDMT (4D Molecular Therapeutics Inc) has a market capitalization of $0.53 billion, making it a small-cap stock.

What is FDMT's price to book ratio?

FDMT trades at a price-to-book (P/B) ratio of 1.29, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Similar Investment Decisions

Explore investment analyses for stocks similar to 4D Molecular Therapeutics Inc

Explore Categories

Disclaimer

This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.